Filed Pursuant to Rule 424(b)(7)
Registration No. 333-269766
Prospectus Supplement No. 5
(To Prospectus dated February 14, 2023)
MULLEN AUTOMOTIVE INC.
242,124,674 Shares
of Common Stock
This
prospectus supplement of Mullen Automotive Inc. (formerly known as Net Element, Inc.), a Delaware corporation (the
“Company” or “Mullen”), relates solely to the resale by the investors listed in the section of this
prospectus entitled “Selling Stockholders” (the “Selling Stockholders”) of up to 242,124,674 shares of our
common stock, par value $0.001 per share (“Common Stock”), including Common Stock issuable upon exercise of
warrants to purchase shares of Common Stock (the “Warrants”), and upon exercise of pre-funded warrants to purchase
shares of Common Stock pursuant to the Settlement Additional Purchase Right and the Acuitas Letter Agreement (each as defined
below) (the “Pre-Funded Warrants”). Except as otherwise indicated, all share and per share information in this
prospectus supplement gives effect to the reverse stock split of our outstanding Common Stock, which was effected at a ratio of
one-for-twenty-five (1-for-25) (the “Reverse Stock Split”) as of 12:01 a.m. Eastern Time on Thursday, May 4, 2023 (the
“Effective Time”).
The Warrants will have an exercise price of the lower of (i) $1.27,
the closing price of the Company’s stock on the date the Securities Purchase Agreement (as defined below) was executed, or (ii) the
closing price of the Common Stock on the trading day immediately preceding the Purchase Date (as defined below), subject to a floor price
of $0.10 per share (as adjusted as provided in the warrants and further in accordance with the Securities Purchase Agreement, dated as
of June 7, 2022 and amended on June 23, 2022, September 19, 2022, November 15, 2022 and April 3, 2023 (the “Securities
Purchase Agreement”)). The Warrants will be exercisable upon issuance and will have a term of five years from the date of issuance.
Additional shares of our Common Stock are being registered for resale pursuant to the terms of the Warrants and the Securities Purchase
Agreement to cover additional shares of Common Stock that may be issuable under the anti-dilution provisions contained in the terms of the Warrants and described herein under “Selling Stockholders” and “Description
of Capital Stock.”
Our registration of the shares of Common Stock
covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of such shares of Common Stock. The Selling
Stockholders may sell the shares of Common Stock covered by this prospectus in a number of different ways and at varying prices. For additional
information on the possible methods of sale that may be used by the Selling Stockholders, you should refer to the section of this prospectus
entitled “Plan of Distribution” of this prospectus. We will not receive any of the proceeds from the shares of Common Stock
sold by the Selling Stockholders, other than any proceeds from any cash exercise of the Warrants.
No underwriter or other person has been engaged
to facilitate the sale of our Common Stock in this offering. The Selling Stockholders and any broker-dealers or agents may, individually
but not severally, be deemed to be an “underwriter” within the meaning of the Securities Act, of the shares of Common Stock
that they are offering pursuant to this prospectus. We will bear all costs, expenses and fees in connection with the registration of such
shares of Common Stock. The Selling Stockholders will bear all commissions and discounts, if any, attributable to their respective sales
of our Common Stock.
You should read this prospectus supplement, the
accompanying prospectus and any related free writing prospectus carefully before you invest. Our common stock is listed on The Nasdaq
Capital Market under the symbol “MULN”. The last reported sale price of our common stock on June 1, 2023, was $0.74 per
share.
Investing in our securities involves risk.
Before buying our securities, you should carefully consider the risks that we have described under the section captioned “Risk Factors”
in this prospectus supplement on page S-5 and on page 2 of the accompanying prospectus, as well as our other filings that
are incorporated by reference into this prospectus supplement and the accompanying prospectus.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation
to the contrary is a criminal offense.
The date of this prospectus supplement is June 5,
2023
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
Page
ABOUT THIS PROSPECTUS SUPPLEMENT
This document is part of an automatic “shelf”
registration statement on Form S-3 (File No. 333-269766) that we filed with the SEC, and is in two parts. The first part
is this prospectus supplement, which describes the specific terms of offering of shares of our common stock and also adds to and updates
information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part,
the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both
parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and
the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of
this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of
these documents is inconsistent with a statement in another document having a later date — for example, a document incorporated
by reference in the accompanying prospectus — the statement in the document having the later date modifies or supersedes the earlier
statement.
We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made
solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties
to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties
or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied
on as accurately representing the current state of our affairs.
We have not authorized anyone to provide any information
other than that contained or incorporated by reference in this prospectus supplement or the accompanying prospectus. We take no responsibility
for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement
and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered
by this prospectus supplement and the accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful
to make such offer or solicitation of an offer in such jurisdiction. The information contained in this prospectus supplement or the accompanying
prospectus, or incorporated by reference herein or therein is accurate only as of the respective dates thereof, regardless of the time
of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our shares of common stock. It is important
for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the documents
incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in
the documents to which we have referred you in the sections entitled “Additional Information” and “Incorporation of
Certain Information by Reference” in this prospectus supplement and in the accompanying prospectus. You should rely only on the
information contained or incorporated by reference in this prospectus supplement.
We are offering to sell, and seeking offers to
buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement
and the accompanying prospectus and the offering of the shares of our common stock in certain jurisdictions may be restricted by law.
Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves
about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus
supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not
constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by
this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to
make such an offer or solicitation.
Mullen Automotive Inc. and its consolidated subsidiaries
are referred to herein as “Mullen,” “the Company,” “we,” “us” and “our,” unless
the context indicates otherwise.
FORWARD-LOOKING STATEMENTS
Some of the statements contained or incorporated
by reference in this prospectus supplement and the accompanying prospectus may include forward-looking statements that reflect our current
views with respect to our research and development activities, business strategy, business plan, financial performance and other future
events. These statements include forward-looking statements both with respect to us, specifically, and the electric vehicle sector, in
general. We make these statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements
that include the words “expect,” “intend,” “plan,” “believe,” “project,” “estimate,”
“may,” “should,” “anticipate,” “will” and similar statements of a future or forward-looking
nature identify forward-looking statements for purposes of the federal securities laws or otherwise.
All forward-looking statements involve inherent
risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated
in these statements. We believe that these factors include, but are not limited to, those factors set forth under the caption “Risk
Factors” in this prospectus supplement, the accompanying prospectus and in our most recent Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q, all of which you should review carefully. Please consider our forward-looking statements in light
of those risks as you read this prospectus supplement and the accompanying prospectus. We undertake no obligation to publicly update or
review any forward-looking statement, whether as a result of new information, future developments or otherwise.
If one or more of these or other risks or uncertainties
materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. All
subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified
in their entirety by this note. Before purchasing any of our securities, you should consider carefully all of the factors set forth or
referred to in this prospectus supplement and the accompanying prospectus that could cause actual results to differ.
PROSPECTUS SUPPLEMENT SUMMARY
The following summary highlights some information
from this prospectus supplement. It is not complete and does not contain all of the information that you should consider before making
an investment decision. You should read this entire prospectus supplement and the accompanying prospectus, including the “Risk Factors”
section on page S-5 and in the documents incorporated by reference, the financial statements and related notes and the other more
detailed information appearing elsewhere or incorporated by reference into this prospectus supplement and the accompanying prospectus.
The Company
Mullen Automotive Inc. is a Southern California-based
electric vehicle company that operates in various verticals of businesses focused within the automotive industry. The Company’s
mission is to build the next-generation of premium passenger electric vehicles (EVs), and a portfolio of commercial vehicles. The
Company was originally formed on April 20, 2010 as a developer and manufacturer of electric vehicle technology. On November 5,
2021, the Company (formerly known as Net Element, Inc.), completed its business combination (the “Merger”) with Mullen
Automotive, Inc. (“Mullen Automotive”), in accordance with the terms of the Second Amended and Restated Agreement and
Plan of Merger, dated as of July 20, 2021, as amended (the “Merger Agreement”), by and among the Company, Mullen Acquisition, Inc.
(“Merger Sub”), Mullen Automotive, and Mullen Technologies, Inc. (“Mullen Technologies”). Pursuant to the
Merger, Merger Sub merged with and into Mullen Automotive, with Mullen Automotive surviving as a wholly owned subsidiary of the Company.
In connection with the Merger, the Company changed its name from “Net Element, Inc.” to “Mullen Automotive Inc.”
The Nasdaq Stock Market, LLC (Nasdaq Capital Market) ticker symbol for the Company’s Common Stock changed from “NETE”
to “MULN” at the opening of trading on November 5, 2021.
Recent Developments
On May 3, 2023, we filed a Certificate of Amendment
to our Second Amended and Restated Certificate of Incorporation (as amended to date) with the Secretary of State of the State of Delaware
to the Reverse Stock Split of our Common Stock.
As a result of the Reverse Stock Split, at the
Effective Time, every twenty-five (25) shares of the Company’s pre-Reverse Stock Split Common Stock was combined and automatically
became one (1) share of Common Stock. the Company’s post-Reverse Stock Split Common Stock began trading on May 4, 2023 with a new
CUSIP number of 62526P208. The Reverse Stock Split did not change the authorized number of shares or the par value of the Common Stock
nor modify any voting rights of the Common Stock.
Also, at the Effective Time, the number of shares
of Common Stock issuable upon exercise of warrants and shares reserved for issuance under the Company’s 2022 Equity Incentive Plan
were proportionately adjusted, using the 1-for-25 ratio, rounded up to the nearest whole share and nearest whole cent. There are currently
no outstanding stock options under the Company’s 2022 Equity Incentive Plan. In addition, the conversion price for each outstanding
share of preferred stock and convertible notes and the exercise price for each outstanding warrant will be increased in inverse proportion
to the 1-for-25 split ratio such that upon conversion or exercise, the aggregate conversion price for conversion of preferred stock or
convertible notes and the aggregate exercise price payable by the warrant holder to the Company for shares of Common Stock subject to
such warrant will remain approximately the same as the aggregate conversion or exercise price, as applicable, prior to the Reverse Stock
Split.
Corporate Information
Our principal offices are located at 1405 Pioneer
St, Brea, CA 92821 and our telephone number is (714) 613-1900. Our website address is https://mullenusa.com/. Our website and the information
contained on, or that can be accessed through, our website shall not be deemed to be incorporated by reference in, and are not considered
part of, this prospectus supplement or the accompanying prospectus. You should not rely on any such information in making your decision
whether to purchase our common stock.
THE OFFERING
| Shares of common stock offered by us: |
242,124,674 shares of our Common
Stock, including Common Stock issuable upon exercise of the Warrants and
the Pre-Funded Warrants. |
| |
|
| Use of proceeds: |
We will not receive any of the proceeds from the sale or other disposition of shares of our Common Stock by the Selling Stockholders. See the section of this prospectus titled “Use of Proceeds.” |
| |
|
| Market for Common Stock: |
Our Common Stock is listed on The NASDAQ Capital Market under the symbol “MULN.” On June 1, 2023, the last reported sale price of our Common Stock on The NASDAQ Capital Market was $0.74 per share. |
| |
|
| Risk factors: |
See “Risk Factors” beginning on page S-5 for risks you should consider before investing in our shares. |
RISK FACTORS
Investing in our securities involves risks. You
should carefully consider the risks, uncertainties and other factors described in the Company’s Annual Report on Form 10-K (File No. 001-34887) filed with the SEC on January 13, 2023, as amended by Amendment No. 1 to our Annual Report on Form 10-K, filed with the Commission on January 30, 2023, and as supplemented and updated by subsequent Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the Securities and Exchange Commission (the
“SEC” or the “Commission”), and in other documents which are incorporated by reference into this prospectus supplement,
as well as the risk factors and other information contained in or incorporated by reference into the accompanying prospectus before investing
in any of our securities. Our financial condition, results of operations or cash flows could be materially adversely affected by any of
these risks. The risks and uncertainties described in the documents incorporated by reference herein are not the only risks and uncertainties
that you may face.
Risks Related to the Offering
The Selling Stockholders may sell a large number of shares, resulting
in substantial diminution to the value of shares of Common Stock held by our current stockholders.
Pursuant to the terms of the Warrants and the Pre-Funded Warrants, the Warrants and the Pre-Funded Warrants may not be exercised, into shares of Common Stock to the extent that the
issuance of shares of Common Stock would cause the Selling Stockholder to beneficially own more than 9.99% of our then outstanding
shares of Common Stock.
However, we do not have the right to control the
timing and amount of any sales by the Selling Stockholders of the shares registered for resale hereunder. In addition, these restrictions
do not prevent the Selling Stockholders from selling shares of Common Stock received in connection with such conversions or exercises
and then receiving additional shares of Common Stock in connection with a subsequent issuance. In this way, the Selling Stockholders could
sell more than 9.99% of the outstanding shares of Common Stock in a relatively short time frame while never holding more than 9.99% at
any one time.
The market price of shares of our Common Stock
could decline as a result of substantial sales of our Common Stock, particularly sales by our directors, executive officers and significant
stockholders. Further, the registration of the sale of shares of our Common Stock hereunder may create a circumstance commonly referred
to as an “overhang” whereby a large number of shares of our Common Stock become available for sale or the perception in the
market that holders of a large number of shares intend to sell their shares.
The existence of an overhang and the anticipation
of such sales, whether or not sales have occurred or are occurring, could cause the market price of our Common Stock to fall. It could
make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at
a time and price that we deem reasonable or appropriate.
Our outstanding shares of convertible preferred stock contain
anti-dilution protection, which may cause significant dilution to our stockholders.
As
of June 1, 2023, we had outstanding 218,361,189 shares of Common Stock. As of that same date, we also had outstanding 1,037
shares of Series A Preferred Stock convertible into an aggregate of 4,148 shares of Common Stock, 1,210,056 shares of Series C
Preferred Stock convertible into an aggregate of 14,523 shares of Common Stock and 363,097 shares of Series D Preferred Stock
convertible into an aggregate of 48,402 shares of Common Stock. The issuance of shares of Common Stock upon the conversion of such shares of
preferred stock would dilute the percentage ownership interest of holders of our Common Stock, dilute the book value per share of our
Common Stock and increase the number of our publicly traded shares, which could depress the market price of our Common Stock.
In addition, the shares of Series D Preferred
Stock contain weighted average anti-dilution provisions which, subject to limited exceptions, would increase the number of shares issuable
upon conversion of such preferred stock (by reducing the conversion price of the Series D Preferred Stock) in the event that we in
the future issue Common Stock, or securities convertible into or exercisable to purchase Common Stock, at a price per share lower than
the conversion price then in effect.
Our commitments to issue shares of Common Stock or securities
that are convertible into shares of Common Stock may cause significant dilution to our stockholders
The Securities Purchase Agreement
provides that the remaining $45 million of the Commitment Amount (as defined in the Securities Purchase Agreement) shall be paid on
June 12, 2023. The purchase price per share of Series D Preferred Stock will be the lower of (i) $1.27, the closing price
of the Company’s stock on the date the Securities Purchase Agreement was executed, or (ii) the closing price of the
Common Stock on the trading day immediately preceding the Purchase Date, subject to a floor price of $0.10 per share. For
no additional consideration, for every share of Series D Preferred Stock purchased, such investor shall receive Warrants
exercisable for 185% shares of Series D Preferred Stock purchased by the investors at an exercise price equal to the purchase
price for shares of Series D Preferred Stock.
The Securities Purchase Agreement further
provides that from April 1, 2023 until June 30, 2023, the investors shall have the right, but not the obligation, at any
time from time to time, in each investors sole and absolute discretion to purchase from the Company additional shares of
Series D Preferred Stock in an amount equal to such investor’s pro rata portion of $100,000,000 on the same terms and
conditions as applicable to the purchase and sale of shares of Series D Preferred Stock as provided under the Securities
Purchase Agreement, including that each investor exercising such right shall receive a proportional amount of Warrants exercisable
for 110% of shares of Series D Preferred Stock purchased by the investors at an exercise price equal to the purchase price for
shares of Series D Preferred Stock.
On January 13, 2023, the Company entered
into Settlement Agreements and Releases (the “Share Issuance Settlement Agreement”) with Acuitas Capital LLC (“Acuitas”)
pursuant to which Acuitas received the right to purchase (the “Settlement Additional Purchase Right”) additional shares of
Series D Preferred Stock and warrants in an amount equal to $20 million on the same terms and conditions as provided under the Securities
Purchase Agreement. The Share Issuance Settlement Agreement was subsequently amended whereby the Acuitas irrevocably exercised the Settlement
Additional Purchase Right effective June 1, 2023 in accordance with the same terms that apply to Additional Purchases (as defined
in the Securities Purchase Agreement); provided, however, that if Acuitas exercises its Settlement Additional Purchase Right, it shall
receive Additional Warrants (as defined in the Series D Securities Purchase Agreement) exercisable for 185% of shares of Common Stock
at an exercise price equal to the closing price of the Common Stock as of May 31, 2023. On June 5, 2023, the Company and Acuitas
entered into a letter agreement (the “Acuitas Letter Agreement”), pursuant to which the Company and Acuitas agreed that in
lieu of the issuance and delivery by the Company of shares of Series D Preferred Stock to Acuitas upon receipt of $20 million paid by
Acuitas on June 1, 2023, the Company will issue shares of Common Stock and Pre-Funded Warrants exercisable for shares of Common Stock.
In addition, on January 13, 2023, the Company
entered into a Settlement Agreement and Release (the “Series D Settlement Agreement” and, together with the Share Issuance
Settlement Agreement, the “Settlement Agreements”) with the investors that entered into the Securities Purchase Agreement
pursuant to which such investors waived the default and all damages that are incurred as a result of any default prior to the registration
of shares of Common Stock underlying the Notes and Warrants issued upon exercise of the Notes issued pursuant to The Securities Purchase Agreement.
In exchange, the Company agreed to grant the investors the right to purchase from the Company additional shares of Series D Preferred
Stock and Warrants in an amount equal to such investor’s pro rata portion of $10 million on the same terms and conditions as applicable
to the purchase and sale of shares of Series D Preferred Stock as provided under the Securities Purchase Agreement (the “Second
Additional Purchase Right”). The Second Additional Purchase Right may be exercised by each investor from time to time, in its sole
and absolute discretion in accordance with the same terms that apply to additional purchases as described in the Securities Purchase Agreement;
provided, however, that any investor that exercises its Second Additional Purchase Right will receive additional five-year warrants exercisable
for 185% of shares of common stock at an exercise price equal to the closing price of the common stock as of the date of the trading day
immediately prior to the exercise of the Second Additional Purchase Right.
Implementation of the Securities Purchase
Agreement and the Settlement Agreements would cause issuance of additional shares Common Stock or issuance of shares Common Stock
upon the conversion of Series D Preferred Stock and exercise of Warrants and Pre-Funded Warrants, which in turn would dilute
the percentage ownership interest of holders of our Common Stock, dilute the book value per share of our Common Stock and increase
the number of our publicly traded shares, which could depress the market price of our Common Stock.
Our commitment to issue shares of Common Stock pursuant to the
terms of the Securities Purchase Agreement, the Settlement Agreements, our preferred stock and the Warrants could encourage short sales
by third parties which could contribute to the future decline of our stock price.
Our commitment to issue shares of Common Stock,
our preferred stock and the Warrants has the potential to cause significant downward pressure on the price of our Common Stock. In such
an environment, short sellers may contribute exacerbate any decline of our stock price. If there are significant short sales of our Common
Stock, the share price of our Common Stock may decline more than it would in an environment without such activity. This may cause other
holders of our Common Stock to sell their shares. If there are many more shares of our Common Stock on the market for sale than the market
will absorb, the price of our common shares will likely decline.
The Selling Stockholders may participate in short
sales of our Common Stock. They may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the
shares of Common Stock in the course of hedging in positions they assume. The Selling Stockholders may also sell shares of Common Stock
short and deliver shares of Common Stock covered by this prospectus to close out short positions and to return borrowed shares in connection
with such short sales. The Selling Stockholders may also loan or pledge shares of Common Stock to broker-dealers that in turn may sell
such shares. Such activity could cause a decline in the market price of the shares of our Common Stock.
USE OF PROCEEDS
We will receive no proceeds from the sale of shares
of Common Stock by the Selling Stockholders.
We
may receive proceeds from the exercise of the Warrants and issuance of the shares of our Common Stock issuable upon exercise of the Warrants.
If all of the Warrants mentioned above were exercised for cash in full, the proceeds would be approximately $[·]
million. We intend to use the net proceeds of such Warrant exercise, if any, for general working capital. We can make no assurances that
any of the Warrants will be exercised, or if exercised, that they will be exercised for cash, the quantity which will be exercised or
in the period in which they will be exercised.
SELLING STOCKHOLDERS
The shares of Common Stock being offered by
the Selling Stockholders are those issued and issuable to the Selling Stockholders, including upon the exercise of the Warrants and
Pre-Funded Warrants. We are registering the Common Stock in order to permit the Selling Stockholders to offer the shares for resale
from time to time. Except for ownership of shares of our Common Stock, our preferred stock, the Warrants and the Pre-Funded
Warrants, the Selling Stockholders have not had any material relationship with us within the past three years.
The table below lists the Selling Stockholders
and other information regarding the beneficial ownership of the shares of Common Stock by the Selling Stockholders. The second column
lists the number of shares of Common Stock beneficially owned by the Selling Stockholders as of June 1, 2023, assuming conversion
of all convertible securities and/or rights held by the Selling Stockholders on that date, without regard to any limitations on exercises.
The third column lists the maximum number of shares of Common Stock being offered by this prospectus supplement by the Selling Stockholders.
Under the terms of our Amended and Restated Certificate
of Incorporation and the terms of the Warrants and the Pre-Funded Warrants, the Selling Stockholders may not convert Series D Preferred
Stock into or exercise Warrants or Pre-Funded Warrants for Common Stock to the extent such conversion or exercise would cause such Selling
Stockholder, together with its affiliates, to beneficially own a number of shares of Common Stock which would exceed 9.99%, as applicable,
of our then outstanding Common Stock following such exercise, excluding for purposes of such determination Common Stock issuable upon
conversion of other convertible securities which have not been converted. The number of shares in the second column does not reflect this
limitation. The Selling Stockholders may sell all, some or none of their shares in this offering. See “Plan of Distribution.”
| Name of Selling Security holder | |
Number of
Shares of
Common
Stock
Owned
Prior to
Offering | |
Maximum
Number of
Shares of
Common
Stock to
be Sold
Pursuant
to this
Prospectus Supplement | |
Number of
Shares of
Common
Stock
Owned
After
Offering | |
Percentage of
Shares of
Common
Stock
Owned
After
Offering if
Greater than
1% |
|
| Michael Wachs 2022 Dynasty Trust (1) | |
199,628,706 | |
53,227,410 | |
189,458,359 | |
47.1 |
% |
| Acuitas Capital LLC (2) | |
259,842,114 | |
161,174,813 | |
180,221,131 | |
45.2 |
% |
| Michael Friedlander (3) | |
1,067,714 | |
166,500 | |
901,214 | |
* |
|
| Jess Mogul (4) | |
9,776,516 | |
3,187,324 | |
9,171,061 | |
4.0 |
% |
| Jim Fallon (5) | |
4,808,255 | |
1,477,597 | |
4,505,528 | |
2.0 |
% |
| Davis-Rice Pty Limited (6) | |
94,348,738 | |
22,891,030 | |
90,110,556 | |
29.2 |
% |
| * |
Represents less than 1% |
| (1) |
Consists of (i) 5,632,791 shares of Common Stock held by Michael Wachs 2022 Dynasty Trust, (ii) 18 shares of Common Stock issuable upon conversion of 458 shares of Series C Preferred Stock, and (iii) 10,170,347 shares of Common Stock issuable upon exercise of warrants held by Esousa Holdings, LLC. Also consists of 183,825,550 shares of Common Stock that may be acquired within 60 days, based on a closing price of $0.74 on June 1, 2023, pursuant to the terms of the Securities Purchase Agreement and the Series D Settlement Agreement. All shares may be deemed to be beneficially owned by Michael Wachs, who serves as the sole Managing Member of Esousa Holdings, LLC and the manager of Michael Wachs 2022 Dynasty Trust. The address for Michael Wachs 2022 Dynasty Trust, Esousa Holdings, LLC and Michael Wachs is 211 E 43rd St, 4th Fl, New York, NY 10017. |
| (2) |
Consists of 19,493,071 shares
of Common Stock, 8,074,124 shares of Common stock issuable upon exercise of Pre-Funded Warrants and 52,053,788 shares of Common Stock
issuable upon exercise of warrants Also consists of 180,221,131 shares of Common Stock that may be acquired within 60 days, based
on a closing price of $0.74 on June 1, 2023, pursuant to the terms of the Securities Purchase Agreement and the Series D Settlement Agreement.
All shares may be deemed to be beneficially owned by Terren Peizer, who serves as the Chief Executive Officer of Acuitas Capital LLC.
The address for Acuitas Capital, LLC is 200 Dorado Beach Drive #3831, Dorado, Puerto Rico 00646. |
| (3) |
Consists of 166,615 shares of Common Stock. Also consists of 901,099 shares of Common Stock that may be acquired
within 60 days, based on a closing price of $0.74 on June 1, 2023, pursuant to the terms of the Securities Purchase Agreement and the
Series D Settlement Agreement. The address for Michael Friedlander is 46 Tarryhill Rd, Tarrytown, NY 10591. |
| (4) |
Consists of 160,000 shares of Common Stock and 605,455 shares of Common Stock issuable upon exercise of warrants. Also consists of 9,011,061 shares of Common Stock that may be acquired
within 60 days, based on a closing price of $0.74 on June 1, 2023, pursuant to the terms of the Securities Purchase Agreement and the
Series D Settlement Agreement. The address for Jess Mogul is 347 W 87 St, Apt 2R, New York, NY 10024. |
| (5) |
302,727 shares of Common Stock issuable upon exercise of warrants Also consists of 4,505,528 shares
of Common Stock that may be acquired within 60 days, based on a closing price of $0.74 on June 1, 2023, pursuant to the terms of the
Securities Purchase Agreement and the Series D Settlement Agreement. The
address for Jim Fallon is 137 West 83rd St, Apt 5W, New York, NY 10024. |
| (6) |
Consists of
4,238,182 shares of Common Stock issuable upon exercise of warrants. Also consists of 90,110,556 shares of Common Stock that
may be acquired within 60 days, based on a closing price of $0.74 on June 1, 2023, pursuant to the terms of the Securities Purchase
Agreement and the Series D Settlement Agreement. Shares held by Davis-Rice Pty Limited may be deemed to be beneficially owned by
Timothy Davis-Rice, who serves as the Director of Davis-Rice Pty Limited. The address for Davis-Rice Pty Limited is 4 Murchison
Street, Mittagong, NSW 2575, Australia. |
PLAN OF DISTRIBUTION
We are registering the shares of Common Stock
to permit the resale of these shares of Common Stock by the holders thereof from time to time after the date of this prospectus supplement.
We will not receive any of the proceeds from the sale by the Selling Stockholders of the shares of Common Stock. We will bear all fees
and expenses incident to our obligation to register the shares of Common Stock
The Selling Stockholders may sell all or a portion
of the shares of Common Stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters,
broker-dealers or agents. If the shares of Common Stock are sold through underwriters or broker-dealers, the Selling Stockholders will
be responsible for underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold in one or
more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale,
or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,
| |
· |
on any national securities exchange or quotation service on which the securities may |
| |
· |
be listed or quoted at the time of sale; |
| |
· |
in the over-the-counter market; |
| |
· |
in transactions otherwise than on these exchanges or systems or in the over-the-counter market; |
| |
· |
through the writing of options, whether such options are listed on an options exchange or otherwise; |
| |
· |
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| |
· |
block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
| |
· |
purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
| |
· |
an exchange distribution in accordance with the rules of the applicable exchange; |
| |
· |
privately negotiated transactions; |
| |
· |
sales pursuant to Rule 144; |
| |
· |
broker-dealers may agree with the selling securityholders to sell a specified number of |
| |
· |
such shares at a stipulated price per share; |
| |
· |
a combination of any such methods of sale; and |
| |
· |
any other method permitted pursuant to applicable law. |
If the Selling Stockholders effect such transactions
by selling shares of Common Stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may
receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers
of the shares of Common Stock for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or commissions
as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In
connection with sales of the shares of Common Stock or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers,
which may in turn engage in short sales of the shares of Common Stock in the course of hedging in positions they assume. The Selling Stockholders
may also sell shares of Common Stock short and deliver shares of Common Stock covered by this prospectus supplement to close out short
positions and to return borrowed shares in connection with such short sales. The Selling Stockholders may also loan or pledge shares of
Common Stock to broker-dealers that in turn may sell such shares. The Selling Stockholders may pledge or grant a security interest in
some or all of the warrants or shares of Common Stock owned by them and, if they default in the performance of their secured obligations,
the pledgees or secured parties may offer and sell the shares of Common Stock from time to time pursuant to this prospectus supplement
or any amendment to the accompanying prospectus under Rule 424(b) or other applicable provision of the Securities Act of 1933,
as amended, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest
as Selling Stockholders under this prospectus supplement. The Selling Stockholders also may transfer and donate the shares of Common Stock
in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus supplement.
The Selling Stockholders and any broker-dealer
participating in the distribution of the shares of Common Stock may be deemed to be “underwriters” within the meaning of the
Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting
commissions or discounts under the Securities Act. At the time a particular offering of the shares of Common Stock is made, a prospectus
supplement, if required, will be distributed which will set forth the aggregate amount of shares of Common Stock being offered and the
terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting
compensation from the Selling Stockholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.
Under the securities laws of some states, the
shares of Common Stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states
the shares of Common Stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption
from registration or qualification is available and is complied with. There can be no assurance that any Selling Stockholder will sell
any or all of the shares of Common Stock registered pursuant to the registration statement, of which this prospectus supplement forms
a part.
The
Selling Stockholders and any other person participating in such distribution will be subject to applicable provisions of the Securities
Exchange Act of 1934, as amended, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange
Act, which may limit the timing of purchases and sales of any of the shares of Common Stock by the Selling Stockholders and any other
participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of Common Stock
to engage in marketmaking activities with respect to the shares of Common Stock. All of the foregoing may affect the marketability of
the shares of Common Stock and the ability of any person or entity to engage in market-making activities with respect to the shares of
Common Stock. We will pay all expenses of the registration of the shares of Common Stock, estimated to be $[·]
in total, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities
or “blue sky” laws; provided, however, that a Selling Stockholder will pay all underwriting discounts and selling commissions,
if any. We will indemnify the Selling Stockholders against liabilities, including some liabilities under the Securities Act, in accordance
with the registration rights agreements, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling
Stockholders against civil liabilities, including liabilities under the Securities Act, that may arise from any written information furnished
to us by the Selling Stockholders specifically for use in this prospectus supplement, in accordance with the related registration rights
agreement, or we may be entitled to contribution. Once sold under the registration statement, of which this prospectus supplement forms
a part, the shares of Common Stock will be freely tradable in the hands of persons other than our affiliates.
DETERMINATION OF OFFERING PRICE
The prices at which the shares of Common Stock
covered by this prospectus supplement may actually be sold will be determined by the prevailing public market price for shares of Common
Stock, by negotiations between the Selling Stockholders and buyers of our Common Stock in private transactions or as otherwise described
in “Plan of Distribution.”
DESCRIPTION OF CAPITAL STOCK
General
We
are authorized to issue up to 5,500,000,000 shares of capital stock, including 5,000,000,000 shares of Common Stock, par value $0.001
per share, and 500,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”), of which 200,000
shares are designated as “Series A Preferred Stock,” 12,000,000 shares are designated as “Series B Preferred
Stock,” 40,000,000 shares are designated as “Series C Preferred Stock” and 437,500,001 shares are designated as
“Series D Preferred Stock.” As of June 1, 2023, we had 218,361,189 shares of Common Stock, 1,037 shares of Series A
Preferred Stock, no shares of Series B Preferred Stock, 1,210,056 shares of Series C Preferred Stock and 363,097 shares of
Series D Preferred Stock issued and outstanding.
The additional shares of our authorized stock
available for issuance may be issued at times and under circumstances so as to have a dilutive effect on earnings per share and on the
equity ownership of the holders of our Common Stock. The ability of our board of directors to issue additional shares of stock could enhance
the board’s ability to negotiate on behalf of the stockholders in a takeover situation but could also be used by the board to make
a change-in-control more difficult, thereby denying stockholders the potential to sell their shares at a premium and entrenching current
management. The following description is a summary of the material provisions of our capital stock. You should refer to our certificate
of incorporation, as amended and bylaws, both of which are on file with the SEC as exhibits to previous SEC filings, for additional information.
The summary below is qualified by provisions of applicable law.
Common Stock
Holders of our Common Stock are each entitled
to cast one vote for each share held of record on all matters presented to stockholders, and shall be entitled to notice of any shareholders’
meeting, in accordance with the bylaws. Cumulative voting is not allowed; the holders of a majority of our outstanding shares of capital
stock may elect all directors. Holders of our Common Stock are entitled to receive such dividends as may be declared by our board out
of funds legally available and, in the event of liquidation, to share pro rata in any distribution of our assets after payment of liabilities.
Our directors are not obligated to declare a dividend. It is not anticipated that we will pay dividends in the foreseeable future. Holders
of our do not have preemptive rights to subscribe to any additional shares we may issue in the future. There are no conversion, redemption,
sinking fund or similar provisions regarding the Common Stock. All outstanding shares of Common Stock are fully paid and nonassessable.
The rights, preferences and privileges of holders
of Common Stock are subject to the rights of the holders of any outstanding shares of preferred stock.
Preferred Stock
We may issue up to 500,000,000 shares of preferred
stock, par value $0.001 per share, in one or more series. Our board of directors is hereby expressly authorized to provide, out of the
unissued shares of preferred stock, for one or more series of preferred stock and, with respect to each such series, to fix the number
of shares constituting such series and the designation of such series, the voting powers of the shares of such series, and the preferences
and relative, participating, optional or other special rights and any qualifications, limitations or restrictions thereof, of the shares
of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock,
and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.
The issuance of preferred stock could decrease
the amount of earnings and assets available for distribution to the holders of Common Stock or adversely affect the rights and powers,
including voting rights, of the holders of Common Stock. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a
change in control of the Company, which could depress the market price of our Common Stock.
Voting Rights
Except as otherwise expressly provided by the
amended and restated certificate of incorporation or as provided by law, the holders of shares of Common Stock and Preferred Stock shall
at all times vote together as a single class on all matters (including the election of directors) submitted to a vote of the stockholders;
provided, however, that, any proposal which adversely affects the rights, preferences and privileges of the Series A, B, C or D Preferred
Stock must be approved by a majority in interest of the affected Series of Preferred Stock, as the case may be. Each holder of Common
Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock will have the right to one vote
per share (on a fully converted basis) held of record by such holder and each holder of Series A Preferred Stock will have the right
to 1000 votes per share (on a fully converted basis) held of record by such holder; provided, however, that after November 5, 2024,
each holder of Series A Preferred Stock will have the right to one vote per share (on a fully converted basis) held of record by
such holder.
Series A Preferred Stock
200,000 shares of Preferred Stock are designated as Series A
Preferred Stock.
| |
· |
Conversion. The Series A Preferred Stock is convertible at the option of each holder at any time on a 4-for-1 basis (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like with respect to the Common Stock). The Series A Preferred Stock will automatically convert into shares of Common Stock on a 4-for-1 basis (as so adjusted) upon the earlier of (i) a Qualified Public Offering (as such term is defined in the amended and restated certificate of incorporation) or (ii) the date specified by written consent or agreement of the holders of the then outstanding shares of Series A Preferred Stock. |
Series B Preferred Stock
12,000,000 shares of Preferred Stock are designated as Series B
Preferred Stock.
| |
· |
Conversion. The Series B Preferred Stock is convertible at the option of each holder at any time into the number of shares of Common Stock determined by dividing the Series B Original Issue Price (plus all unpaid accrued and accumulated dividends thereon, as applicable, whether or not declared), by the Series B Conversion Price, as applicable (in each case, the “Conversion Rate”), in effect on the date the certificate is surrendered for conversion. “Series B Original Issue Price” means $0.6877 per share for each share of the Series B Preferred Stock (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like with respect to the Series B Preferred Stock). The initial “Series B Conversion Price” is the Series B Original Issue Price, subject to adjustment as set forth in the amended and restated certificate of incorporation. Based on this formula, the Series B Preferred Stock is currently convertible into Common Stock on a 1-for-25 basis. The Series B Preferred Stock will automatically convert into shares of Common Stock upon the earlier of (i) a Qualified Public Offering (as such term is defined in the amended and restated certificate of incorporation) or (ii) the date specified by written consent or agreement of the holders of the then outstanding shares of Series B Preferred Stock. The Series B Preferred Stock will not be convertible by a holder to the extent that the holder or any of its affiliates would beneficially own in excess of 9.99% of the Common Stock, subject to certain protections as provided in the amended and restated certificate of incorporation. |
Series C Preferred Stock
40,000,000 Shares of Preferred Stock are designated as Series C
Preferred Stock.
| |
· |
Conversion. The Series C Preferred Stock is convertible at the option of each holder at any time into the number of shares of Common Stock determined by dividing the Series C Original Issue Price (plus all unpaid accrued and accumulated dividends thereon, as applicable, whether or not declared), by the Series C Conversion Price, as applicable (in each case, the “Conversion Rate”), in effect on the date the certificate is surrendered for conversion. The initial “Series C Conversion Price” is the Series C Original Issue Price, subject to adjustment as set forth in the amended and restated certificate of incorporation. Based on this formula, the Series C Preferred Stock is currently convertible into Common Stock on a 1-for-25 basis. All of the Series C Preferred Stock shall automatically convert into Common Stock at any such time as (i) the shares underlying the Series C Preferred Stock are subject to an effective registration statement, (ii) the trading price for the Common Stock is more than two times the Series C Conversion Price for twenty (20) trading days in any period of thirty (30) consecutive trading days on Nasdaq CM and (iii) the average daily trading dollar volume of the Common Stock during such twenty trading days is equal to or greater than $4.0 million. The Series C Preferred Stock will not be convertible by a holder to the extent that the holder or any of its affiliates would beneficially own in excess of 9.99% of the Common Stock, subject to certain protections as provided in the amended and restated certificate of incorporation. |
| |
· |
Dividends. The Series C Preferred Stock bears a cumulative 15.0% per annum fixed dividend payable no later than the 5th day after the end of each month on the Series C Original Issue Price plus unpaid accrued and accumulated dividends. “Series C Original Issue Price” means $0.6877 per share for each share of the Series C Preferred Stock (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like with respect to the Series C Preferred Stock). Dividends on the Series C Preferred Stock are prior to any dividends on any other series of Preferred Stock or the Common Stock. The Company may elect to pay dividends for any month with a paid-in-kind election (“PIK”) if (i) the shares issuable further to the PIK are subject to an effective registration statement, (ii) the Company is then in compliance with all listing requirements of Nasdaq and (iii) the average daily trading dollar volume of the Company’s common stock for ten trading days in any period of twenty consecutive trading days on the NASDAQ is equal to or greater than $2 million. |
| |
· |
Redemption Rights. There is no mandatory redemption date, but, subject to the conditions set forth below, all, but not less than all, of the shares are redeemable by the Company at any time, provided that if the Company issues notice to redeem, investor shall have fifteen (15) days to convert such shares to common stock prior to the date of redemption. The redemption price is equal to the Series C Original Issue Price, plus accrued and accumulated dividends, (whether or not declared (the “Series C Redemption Price”). The conditions to the redemption are as follows: (i) the shares have been issued and outstanding for at least one (1) year, (ii) the issuance of the shares of Common Stock underlying the shares has been registered pursuant to the Securities Act and the registration statement is effective, and (iii) the trading price for the Common Stock is less than the Series C Conversion Price (as such term is defined in the amended and restated certificate of incorporation) for twenty (20) trading days in any period of thirty (30) consecutive trading days on the Nasdaq CM. In addition to the above, the shares are also redeemable in accordance with the following schedule provided the issuance of shares of Common Stock underlying the shares has been registered and the registration statement remains effective: |
| |
· |
Year 1: No Redemption |
| |
· |
Year 2: Redemption at 120% of the Series C Redemption Price |
| |
· |
Year 3: Redemption at 115% of the Series C Redemption Price |
| |
· |
Year 4: Redemption at 110% of the Series C Redemption Price |
| |
· |
Year 5: Redemption at 105% of the Series C Redemption Price |
| |
· |
Year 6 and thereafter: Redemption at 100% of the Series C Redemption Price |
Series D Preferred Stock
437,500,001 Shares of Preferred Stock are designated as
Series D Preferred Stock.
Voting Rights. Except as provided by law,
the Series D Preferred Stock will have no voting rights except that approval from a majority in interest of the Series D Preferred
Stock, voting as a separate class, is required in the case of (i) a voluntary dissolution, liquidation or winding up of the Company
or voluntary petition for bankruptcy or assignment for the benefit of creditors, (ii) a merger or consolidation of the Company with
or into another entity, (iii) a Liquidation Event (as defined in the Company’s Second Amended and Restated Certificate of Incorporation),
(iv) any amendment to the Second Amended and Restated Certificate of Incorporation or the Company’s bylaws which adversely
affects the rights, preferences and privileges of the Series D Preferred, or (v) any authorization or issuance of any equity
security (including any other security convertible into or exercisable for any such equity security) having a preference over or parity
with the Series D Preferred Stock.
Conversion. The Series D Preferred
Stock is automatically converted into shares of Common Stock at the applicable Conversion Rate at the time in effect immediately upon
(A) the issuance of shares of Common Stock underlying the Series D Preferred Stock being registered pursuant to the Securities
Act and such registration remaining effective, (B) the trading price for the Company’s Common Stock being more than two times
the Series D Conversion Price for 20 trading days in any period of 30 consecutive trading days on the Nasdaq Capital Market, and
(C) the average daily trading dollar volume of Common Stock during such 20 trading days is equal to or greater than $27.5 million.
The Series D Preferred Stock is convertible at the option of each holder at any time into the number of shares of Common Stock determined
by dividing the Series D Original Issue Price (plus all unpaid accrued and accumulated dividends thereon, as applicable, whether
or not declared), by the Series D Conversion Price (the “Conversion Rate”), in effect on the date the certificate is
surrendered for conversion. The initial “Series D Conversion Price” is the Series D Original Issue Price, subject
to adjustment as set forth in the amended and restated certificate of incorporation. The Series D Preferred Stock will not be convertible
by a holder to the extent that the holder or any of its affiliates would beneficially own in excess of 9.99% of the Common Stock, subject
to certain protections as provided in the amended and restated certificate of incorporation.
Dividends. The Series D Preferred
Stock bears a cumulative 15.0% per annum fixed dividend payable no later than the 5th day after the end of each month on the Series D
Original Issue Price plus unpaid accrued and accumulated dividends. “Series D Original Issue Price” means for each share
of the Series D Preferred Stock the lower of (i) $1.27 or (ii) the closing price of the Common Stock on the trading day
immediately preceding the Purchase Date (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like
with respect to the Series D Preferred Stock). Dividends on the Series D Preferred Stock will be prior to any dividends on any
other series of Preferred Stock or the Common Stock. The Company may elect to pay dividends for any month with a paid-in-kind election
(“PIK”) if (i) the shares issuable further to the PIK are subject to an effective registration statement, (ii) the
Company is then in compliance with all listing requirements of Nasdaq and (iii) the average daily trading dollar volume of the Company’s
common stock for ten trading days in any period of twenty consecutive trading days on the NASDAQ is equal to or greater than $27.5 million.
Redemption Rights. There is no mandatory
redemption date, but, subject to the conditions set forth below, all, but not less than all, of the shares will be redeemable by the Company
at any time, provided that if the Company issues notice to redeem, investors shall have 15 days to convert such shares to Common Stock
prior to the date of redemption. The redemption price will be equal to the Series D Original Issue Price, plus accrued and accumulated
dividends, (whether or not declared (the “Series D Redemption Price”). The conditions to the redemption will be follows:
(i) the shares have been issued and outstanding for at least one year, (ii) the issuance of the shares of Common Stock underlying
the shares has been registered pursuant to the Securities Act and the registration statement is effective, and (iii) the trading
price for the Common Stock is less than the Series D Conversion Price (as such term is defined in the amended and restated certificate
of incorporation) for 20 trading days in any period of 30 consecutive trading days on the Nasdaq CM. In addition to the above, the shares
will also be redeemable in accordance with the following schedule provided the issuance of shares of Common Stock underlying the shares
has been registered and the registration statement remains effective:
| |
· |
Year 2: Redemption at 120% of the Series D Redemption Price |
| |
· |
Year 3: Redemption at 115% of the Series D Redemption Price |
| |
· |
Year 4: Redemption at 110% of the Series D Redemption Price |
| |
· |
Year 5: Redemption at 105% of the Series D Redemption Price |
| |
· |
Year 6 and thereafter: Redemption at 100% of the Series D Redemption Price |
Anti-Takeover Effects of Certain Provisions of Delaware Law and
Our Certificate of Incorporation and Bylaws
Our Certificate of Incorporation, as amended,
and Bylaws, as amended contain provisions that could have the effect of discouraging potential acquisition proposals or tender offers
or delaying or preventing a change of control. These provisions, summarized below, are expected to discourage certain types of coercive
takeover practices and inadequate takeover bids and are designed to encourage persons seeking to acquire control of us to negotiate with
our board of directors. We believe that the benefits of increased protection against an unfriendly or unsolicited proposal to acquire
or restructure us outweigh the disadvantages of discouraging such proposals. Among other things, negotiation of such proposals could result
in an improvement of their terms. These provisions are as follows:
| |
· |
Stockholder Meetings. Under our bylaws, only the Board of Directors, the chairman of the Board, the chief executive officer, or the president (in the absence of a chief executive officer) may call special meetings of stockholders. |
| |
· |
No Cumulative Voting. Our amended and restated certificate of incorporation and bylaws do not provide for cumulative voting in the election of directors. |
| |
· |
Amendment of Provisions in the Amended and Restated Certificate of Incorporation. The amended and restated certificate of incorporation will generally require the affirmative vote of the holders of at least a majority of the outstanding voting stock in order to amend any provisions of the amended and restated certificate of incorporation concerning, among other things: |
| |
· |
the required vote to amend certain provisions of the amended and restated certificate of incorporation; and |
| |
· |
the reservation of the Board of Director’s right to amend the amended and restated bylaws. |
| |
· |
Amendment of the bylaws. An amendment of the bylaws by stockholders requires the affirmative vote of the holders of at least a majority of the outstanding voting stock. |
We are subject to the provisions of Section 203
of the Delaware General Corporation Law, an anti- takeover law. Subject to certain exceptions, the statute prohibits a publicly held Delaware
corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years
after the date of the transaction in which the person became an interested stockholder unless:
| |
· |
prior to such date, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; |
| |
· |
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least eighty-five percent 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned (1) by persons who are directors and also officers and (2) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
| |
· |
on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-thirds percent 662∕3% of the outstanding voting stock that is not owned by the interested stockholder. |
Generally, for purposes of Section 203, a
“business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the
interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns or, within
three (3) years prior to the determination of interested stockholder status, owned fifteen percent (15%) or more of a corporation’s
outstanding voting securities.
Potential Effects of Authorized but Unissued Stock
We have shares of common stock and preferred stock
available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes,
including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital
stock.
The existence of unissued and unreserved common
stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred
stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender
offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, the board of directors has the discretion
to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights,
redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the DGCL
and subject to any limitations set forth in our Certificate of Incorporation. The purpose of authorizing the board of directors to issue
preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with
a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with possible
financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire,
or could discourage a third-party from acquiring, a majority of our outstanding voting stock.
Warrants
The exercise price of
the Warrants will be the lower of (i) $1.27 or (ii) the closing price of the Common Stock on the trading day immediately preceding
the Purchase Date, subject to a floor price of $0.10 per share. The Company must reserve out of authorized and unissued shares a number
of shares of Common Stock equal to 250% of the maximum number of shares of Common Stock that are issuable upon exercise of the Warrants
from time to time. If the Company fails to timely deliver shares upon exercise of the Warrant, the Company will be required to either
(A) pay the holder for each trading day on which shares are not delivered 1% of the product of the number of shares not so issued
multiplied by the closing sale price of the Common Stock on the trading day immediately preceding the required delivery date, or (B) if
the holder purchases shares of Common Stock in anticipation of delivery of shares upon exercise of the Warrant, cash in an amount equal
to holder’s total purchase price of such shares.
The Warrants will provide
for cashless exercise pursuant to which the holder will receive upon exercise a “net number” of shares of Common Stock determined
according to the following formula (the “Cashless Exercise”):
Net Number
= (A x B) / C
For purposes of the foregoing
formula:
| |
A= |
The total number of shares with respect to which the Warrant is then being exercised. |
| |
B= |
The Black Scholes Value (as described below). |
| |
C= |
The lower of the two Closing Bid Prices of the Common Stock in the two days prior the time of such exercise (as such Closing Bid Price is defined in Section 16 herein), but in any event not less than $0.01(as may be adjusted for stock dividends, subdivisions, or combinations in the manner described in Section 2(a) of the Series D Securities Purchase Agreement). |
For purposes of the Cashless
Exercise, “Black Scholes Value” means the Black Scholes value of an option for one share of Common Stock at the date of the
applicable Cashless Exercise, as such Black Scholes value is determined, calculated using the Black Scholes Option Pricing Model obtained
from the “OV” function on Bloomberg utilizing (i) an underlying price per share equal to the Exercise Price, as adjusted,
(ii) a risk-free interest rate corresponding to the U.S. Treasury rate, (iii) a strike price equal to the Exercise Price in
effect at the time of the applicable Cashless Exercise, (iv) an expected volatility equal to 135%, and (v) a deemed remaining
term of the Warrant of 5 years (regardless of the actual remaining term of the Warrant).
The exercise price and
number of shares issuable upon exercise of the Warrants will further be adjusted upon the occurrence of certain events and holders will
be allowed to participate in certain issuances and distributions (subject to certain limitations and restrictions), including certain
stock dividends and splits, dilutive issuances of additional common stock, and dilutive issuances of, or changes in option price or rate
of conversion of, options or convertible securities, as well as the issuance of purchase rights or distributions of assets.
If, during restricted
period, the Company effects a subsequent financing, including the issuance of options and convertible securities, any Common Stock, issued
or sold or deemed to have been issued or sold) for a consideration per share less than a price equal to the current exercise price of
the Warrant (a “Dilutive Issuance”), then immediately after such issuance, the exercise price will be reduced (and in no event
increased) to the price per share as determined in accordance with the following formula:
EP2 = EP1
x (A + B) / (A + C)
For purposes of the foregoing formula:
| |
A= |
The total number of Warrant Shares with respect to which this Warrant may be exercised. |
| |
B= |
The total number of shares of Common Stock that would be issued or issuable under the Dilutive Issuance if issued at a per share equal to EP1. |
| |
C= |
The total number of shares of Common Stock actually issued or issuable under the Dilutive Issuance. |
| |
EP1= |
The Exercise Price in effect immediately prior to a Dilutive Issuance. |
| |
EP2= |
The Exercise Price immediately after such Dilutive Issuance; provided, however, that such price shall in no event be less than $0.01 per share of Common Stock. |
“Purchase Date”
means the 90th day following the date on which a registration statement covering the registration for resale of securities
issued during May 2022 pursuant to additional investment rights provided in the Exchange Agreement dated May 7, 2021 and a $20
million securities purchase agreement.
“Restricted period”
means the period commencing on the Purchase Date and ending on the earlier of (i) the date immediately following the 90th day after
a registration statement registering for the securities has been declared effective by the SEC and (ii) the 90th day after the securities
purchased are saleable under Rule 144 without the requirement for current public information and without volume or manner of sale
limitations.
The Warrants will provide
for certain purchase rights whereby if the Company grants, issues or sells any options, convertible securities or rights to purchase stock,
warrants, securities or other property pro rata to the record holders of any class of Common Stock, then the holder will be entitled to
acquire such purchase rights which the holder could have acquired if the holder had held the number of shares of Common Stock acquirable
upon complete exercise of the Warrant.
The exercisability of
the Warrants may also be limited if, upon exercise, the holder and its affiliates would in aggregate beneficially own more than 9.99%
of the Common Stock.
The Company would also
agree not to enter into any fundamental, transaction, such as a merger, sale of more than 50% of the outstanding voting shares, sale of
substantially all assets, or business combination, unless the successor entity assumes all of the obligations of the Company under the
Warrants and the other transaction documents related to the Warrants.
Transfer Agent and Registrar
The transfer agent and registrar for our Common
Stock is Continental Stock Transfer & Trust Company.
LEGAL MATTERS
The validity of the securities offered hereby
will be passed upon for us by McDermott, Will & Emery LLP.
EXPERTS
The consolidated financial statements at September 30,
2022 and 2021 and for the years then ended incorporated by reference in this prospectus supplement have been so incorporated in reliance
on the report of Daszkal Bolton LLP, an independent registered public accounting firm, incorporated herein by reference, given on the
authority of said firm as experts in auditing and accounting.
ADDITIONAL INFORMATION
This prospectus supplement and the accompanying
prospectus are part of a registration statement on Form S-3 that we have filed with the SEC relating to the securities being offered
hereby. This prospectus supplement and the accompanying prospectus do not contain all of the information in the registration statement
and its exhibits. The registration statement, its exhibits and the documents incorporated by reference in this prospectus supplement and
the accompanying prospectus and their exhibits, all contain information that is material to the offering of the securities hereby. Whenever
a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts or other documents, the reference
may not be complete. You should refer to the exhibits that are a part of the registration statement in order to review a copy of the contract
or documents. The registration statement and the exhibits are available at the SEC’s Public Reference Room or through its website.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. You can read and copy any materials we file with the SEC at its Public Reference
Room at 100 F Street, N.E., Washington, D.C. 20549 and at its regional offices, a list of which is available on the Internet at http://www.sec.gov/contact/addresses.htm.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet
site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, such as us,
that file electronically with the SEC. Additionally, you may access our filings with the SEC through our website at https://investors.mullenusa.com/.
The information on our website is not part of this prospectus.
We will provide you without charge, upon your
oral or written request, with a copy of any or all reports, proxy statements and other documents we file with the SEC, as well as any
or all of the documents incorporated by reference in this prospectus or the registration statement (other than exhibits to such documents
unless such exhibits are specifically incorporated by reference into such documents). Requests for such copies should be directed to:
Mullen Automotive Inc.
Attn: David Michery, President, CEO and Chairman
1405 Pioneer St
Brea, CA 92821
(714) 613-1900
You should rely only on the information in this
prospectus supplement, the accompanying prospectus and the additional information described above and under the heading “Incorporation
of Certain Information by Reference” below. We have not authorized any other person to provide you with different information. If
anyone provides you with different or inconsistent information, you should not rely upon it. We are not making an offer to sell these
securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information in this prospectus supplement
was accurate on the date of the front cover of this prospectus supplement only. Our business, financial condition, results of operations
and prospects may have changed since that date.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to “incorporate by reference”
information that we file with it into this prospectus supplement, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is an important part of this prospectus supplement. The information
incorporated by reference is considered to be a part of this prospectus supplement, and information that we file later with the SEC will
automatically update and supersede information contained in this prospectus supplement and the accompanying prospectus.
We incorporate by reference the documents listed
below that we have previously filed with the SEC:
| |
· |
The Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022, as filed with the Commission on January 13, 2023, as amended by Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed with the Commission on January 30, 2023. |
| |
|
|
| |
· |
The Company’s Quarterly Reports on Form 10-Q for the quarters ended December 31, 2022 and March 31, 2023, filed with the Commission on February 14, 2023 and May 15, 2023, respectively. |
| |
|
|
| |
· |
The Company’s Current Reports on Form 8-K filed with the Commission on October 14, 2022, October 17, 2022, October 21, 2022, November 14, 2022 (Two Filings), November 21, 2022, December 2, 2022, December 15, 2022, December 23, 2022, January 13, 2023, January 23, 2023, January 31, 2023, March 3, 2023, March 6, 2023, March 10, 2023, March 20, 2023, April 7, 2023, April 14, 2023, April 20, 2023, May 5, 2023 and May 19, 2023. |
| |
|
|
| |
· |
The description of the Company’s securities contained in the Prospectus, dated February 14, 2023, filed with the Commission on February 14, 2023 pursuant to Rule 424(b)(4) under the Securities Act (File No. 333-269766), relating to the Company’s registration statement on Form S-3 (File No. 333-269766) filed with the Commission on February 14, 2023, together with any amendment thereto filed with the Commission for the purpose of updating such description. |
All reports and other documents that we file with
the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement and prior
to effectiveness of the registration statement and after the date of this prospectus supplement but before the termination of the offering
of the securities hereunder will also be considered to be incorporated by reference into this prospectus supplement from the date of the
filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other
information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus supplement.
We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus supplement,
upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless
the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner
set forth under the heading “Additional Information,” above.
PROSPECTUS
MULLEN AUTOMOTIVE INC.
Shares of Common Stock
Preferred Stock
Warrants
From time to time, we or selling shareholders
may offer and sell any combination of the securities described in this prospectus, either individually or in combination with other securities.
We or selling shareholders may also offer Common Stock upon conversion of Preferred Stock, or Common Stock or Preferred Stock upon the
exercise of Warrants.
Each time we sell securities pursuant to this
prospectus, we will provide the specific terms of these offerings and securities in one or more prospectus supplements and attach it
to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings.
The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus.
You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the
documents incorporated by reference, before buying any of the securities being offered.
Our Common Stock is listed on The NASDAQ Capital
Market under the symbol “MULN”. On February 8, 2023, the last reported sale price of our Common Stock on The NASDAQ
Capital Market was $0.39 per share.
Investing in our securities involves risk.
You should carefully consider the risks that we have described under the section captioned “Risk Factors” in this prospectus
on page 2 before buying our Securities.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
The date of this prospectus is February 14,
2023
TABLE OF CONTENTS
Page
Mullen Automotive Inc. and its consolidated subsidiaries
are referred to herein as “Mullen,” “the Company,” “we,” “us” and “our,”
unless the context indicates otherwise.
You may only rely on the information contained
in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus
does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the securities offered by this prospectus.
This prospectus and any future prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities
in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus or any prospectus supplement
nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in our affairs since
the date of this prospectus or such prospectus supplement or that the information contained by reference to this prospectus or any prospectus
supplement is correct as of any time after its date.
FORWARD-LOOKING STATEMENTS
Some of the statements contained or incorporated
by reference in this prospectus may include forward- looking statements that reflect our current views with respect to our research and
development activities, business strategy, business plan, financial performance and other future events. These statements include forward-looking
statements both with respect to us, specifically, and the electric vehicle sector, in general. We make these statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include the words “expect,”
“intend,” “plan,” “believe,” “project,” “estimate,” “may,” “should,”
“anticipate,” “will” and similar statements of a future or forward-looking nature identify forward-looking statements
for purposes of the federal securities laws or otherwise.
All forward-looking statements involve inherent
risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated
in these statements. We believe that these factors include, but are not limited to, those factors set forth under the caption “Risk
Factors” in this prospectus and in our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q,
all of which you should review carefully. Please consider our forward- looking statements in light of those risks as you read this prospectus.
We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future
developments or otherwise.
If one or more of these or other risks or uncertainties
materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. All
subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified
in their entirety by this Note. Before purchasing any of our securities, you should consider carefully all of the factors set forth or
referred to in this prospectus that could cause actual results to differ.
PROSPECTUS SUMMARY
The following summary highlights some information
from this prospectus. It is not complete and does not contain all of the information that you should consider before making an investment
decision. You should read this entire prospectus, including the “Risk Factors” section on page 2, the financial statements
and related notes and the other more detailed information appearing elsewhere or incorporated by reference into this prospectus.
The Company
Mullen Automotive Inc. is a Southern California-based
electric vehicle company that operates in various verticals of businesses focused within the automotive industry. The Company’s
mission is to build the next-generation of premium passenger electric vehicles (EVs), and a portfolio of commercial vehicles. The Company
was originally formed on April 20, 2010 as a developer and manufacturer of electric vehicle technology. On November 5, 2021,
the Company (formerly known as Net Element, Inc.), completed its business combination (the “Merger”) with Mullen Automotive, Inc.
(“Mullen Automotive”), in accordance with the terms of the Second Amended and Restated Agreement and Plan of Merger, dated
as of July 20, 2021, as amended (the “Merger Agreement”), by and among the Company, Mullen Acquisition, Inc. (“Merger
Sub”), Mullen Automotive, and Mullen Technologies, Inc. (“Mullen Technologies”). Pursuant to the Merger, Merger
Sub merged with and into Mullen Automotive, with Mullen Automotive surviving as a wholly owned subsidiary of the Company. In connection
with the Merger, the Company changed its name from “Net Element, Inc.” to “Mullen Automotive Inc.”
The Nasdaq Stock Market, LLC (Nasdaq Capital Market) ticker symbol for the Company’s Common Stock changed from “NETE”
to “MULN” at the opening of trading on November 5, 2021.
Corporate Information
Our principal offices are located at 1405 Pioneer
St, Brea, CA 92821 and our telephone number is (714) 613-1900. Our website address is https://mullenusa.com/. Our website and the information
contained on, or that can be accessed through, our website shall not be deemed to be incorporated by reference in, and are not considered
part of, this prospectus. You should not rely on any such information in making your decision whether to purchase our common stock.
RISK FACTORS
Investing in our securities involves risks. You
should carefully consider the risks, uncertainties and other factors described in the Company’s Annual
Report on Form 10-K (File No. 001-34887) filed with the SEC on January 13, 2023, as amended by Amendment
No. 1 to our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed with the Commission on January 30,
2023, and as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that
we have filed or will file with the Securities and Exchange Commission (the “SEC” or the “Commission”), and in
other documents which are incorporated by reference into this prospectus, as well as the risk factors and other information contained
in or incorporated by reference into any accompanying prospectus supplement before investing in any of our securities. Our financial
condition, results of operations or cash flows could be materially adversely affected by any of these risks. The risks and uncertainties
described in the documents incorporated by reference herein are not the only risks and uncertainties that you may face.
USE OF PROCEEDS
Except as described in any applicable prospectus
supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we intend to use the
net proceeds from the sale of the securities under this prospectus for general corporate purposes, which may include funding research
and development and sales and marketing activities, increasing our working capital, acquisitions or investments in businesses, products
or technologies that are complementary to our own, and capital expenditures. We will set forth in the applicable prospectus supplement
our intended use for the net proceeds received from the sale of any securities. Pending the use of the net proceeds, we intend to invest
the net proceeds in short-term, investment-grade, interest-bearing securities.
Unless the applicable prospectus supplement provides
otherwise, we will not receive any of the proceeds from the sale of our securities by selling stockholders.
SELLING STOCKHOLDERS
Selling stockholders are persons or entities that,
directly or indirectly, have acquired or will from time to time acquire from us, our securities. If the registration statement of which
this prospectus forms a part is used by selling stockholders for the resale of any securities registered thereunder pursuant to a registration
rights agreement between us and such selling stockholders or otherwise, information about such selling stockholders, their beneficial
ownership of our securities and their relationship with us will be set forth in a prospectus supplement.
PLAN OF DISTRIBUTION
We or selling stockholders may sell the securities
from time to time pursuant to underwritten public offerings, “at-the-market” offerings, negotiated transactions, block trades
or a combination of these methods. We or selling stockholders may sell the securities to or through one or more underwriters or dealers
(acting as principal or agent), through agents, or directly to one or more purchasers. We or selling stockholders may distribute securities
from time to time in one or more transactions:
| |
· |
at a fixed price or prices, which may be changed; |
| |
|
|
| |
· |
at market prices prevailing at the time of sale; |
| |
|
|
| |
· |
at prices related to such prevailing market prices; or |
| |
|
|
| |
· |
at negotiated prices. |
A prospectus supplement or supplements (and any
related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:
| |
· |
the name or names of the underwriters, dealers or agents, if any; |
| |
|
|
| |
· |
the name or names of the selling stockholders, if any; |
| |
|
|
| |
· |
the purchase price of the securities or other consideration therefor, and the proceeds, if any,
we will receive from the sale; |
| |
|
|
| |
· |
any over-allotment or other options under which underwriters may purchase additional securities
from us or any selling securityholders; |
| |
|
|
| |
· |
any agency fees or underwriting discounts and other items constituting agents’ or underwriters’
compensation; |
| |
|
|
| |
· |
any public offering price; |
| |
|
|
| |
· |
any discounts or concessions allowed or re-allowed or paid to dealers; and |
| |
|
|
| |
· |
any securities exchange or market on which the securities may be listed. |
Only underwriters named
in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. Dealers and agents participating
in the distribution of the securities may be deemed to be underwriters, and compensation received by them on resale of the securities
may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory
liabilities under the Securities Act.
If underwriters are used
in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions
at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase
the securities will be subject to the conditions set forth in the applicable underwriting agreement. We or selling stockholders may offer
the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate.
Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement,
other than securities covered by any over-allotment option. If a dealer is used in the sale of securities, we, a selling stockholder,
or an underwriter will sell the securities to the dealer, as principal. The dealer may then resell the securities to the public at varying
prices to be determined by the dealer at the time of resale. To the extent required, we will set forth in the prospectus supplement the
name of the dealer and the terms of the transaction. Any public offering price and any discounts or concessions allowed or re-allowed
or paid to dealers may change from time to time.
We or selling stockholders
may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement, naming
the underwriter, dealer or agent, the nature of any such relationship.
We or selling stockholders
may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale
of securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement
states otherwise, the agent will act on a best-efforts basis for the period of its appointment.
We may provide agents, underwriters and dealers
with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments
that the agents, underwriters or dealers may make with respect to these liabilities. Agents, underwriters and dealers, or their affiliates,
may engage in transactions with, or perform services for, us in the ordinary course of business.
Selling stockholders may be deemed to be underwriters
under the Securities Act in connection with the securities they resell and any profits on the sales may be deemed to be underwriting
discounts and commissions under the Securities Act.
All securities we may offer, other than Common
Stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but
will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of
the trading markets for any securities.
Any underwriter may engage in over-allotment,
stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment
involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions
involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution
is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities
originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause
the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities
at any time.
Any underwriters that are qualified market makers
on The Nasdaq Capital Market may engage in passive market making transactions in the Common Stock on The Nasdaq Capital Market in accordance
with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers
or sales of the Common Stock. Passive market makers must comply with applicable volume and price limitations and must be identified as
passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid
for such security; if all independent bids are lowered below the passive market maker’s bid, however, the passive market maker’s
bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities
at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
DESCRIPTION OF CAPITAL STOCK
General
We are authorized to issue up to 5,500,000,000
shares of capital stock, including 5,000,000,000 shares of Common Stock, par value $0.001 per share, and 500,000,000 shares of preferred
stock, par value $0.001 per share (the “Preferred Stock”), of which 200,000 shares are designated as “Series A
Preferred Stock,” 12,000,000 shares are designated as “Series B Preferred Stock,” 40,000,000 shares are designated
as “Series C Preferred Stock” and 437,500,001 shares are designated as “Series D Preferred Stock.”
As of February 8, 2023, we had 218,361,189 shares of Common Stock, 1,037 shares of Series A Preferred Stock, no shares of
Series B Preferred Stock, 1,210,056 shares of Series C Preferred Stock and 363,097 shares of Series D Preferred Stock
issued and outstanding.
The additional shares of our authorized stock
available for issuance may be issued at times and under circumstances so as to have a dilutive effect on earnings per share and on the
equity ownership of the holders of our Common Stock. The ability of our board of directors to issue additional shares of stock could
enhance the board’s ability to negotiate on behalf of the stockholders in a takeover situation but could also be used by the board
to make a change-in-control more difficult, thereby denying stockholders the potential to sell their shares at a premium and entrenching
current management. The following description is a summary of the material provisions of our capital stock. You should refer to our certificate
of incorporation, as amended and bylaws, both of which are on file with the SEC as exhibits to previous SEC filings, for additional information.
The summary below is qualified by provisions of applicable law.
Common Stock
Holders of our Common Stock are each entitled
to cast one vote for each share held of record on all matters presented to stockholders, and shall be entitled to notice of any shareholders’
meeting, in accordance with the bylaws. Cumulative voting is not allowed; the holders of a majority of our outstanding shares of capital
stock may elect all directors. Holders of our Common Stock are entitled to receive such dividends as may be declared by our board out
of funds legally available and, in the event of liquidation, to share pro rata in any distribution of our assets after payment of liabilities.
Our directors are not obligated to declare a dividend. It is not anticipated that we will pay dividends in the foreseeable future. Holders
of our do not have preemptive rights to subscribe to any additional shares we may issue in the future. There are no conversion, redemption,
sinking fund or similar provisions regarding the Common Stock. All outstanding shares of Common Stock are fully paid and nonassessable.
The rights, preferences and privileges of holders
of Common Stock are subject to the rights of the holders of any outstanding shares of preferred stock.
Preferred Stock
We may issue up to 500,000,000 shares of preferred
stock, par value $0.001 per share, in one or more series. Our board of directors is hereby expressly authorized to provide, out of the
unissued shares of preferred stock, for one or more series of preferred stock and, with respect to each such series, to fix the number
of shares constituting such series and the designation of such series, the voting powers of the shares of such series, and the preferences
and relative, participating, optional or other special rights and any qualifications, limitations or restrictions thereof, of the shares
of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock,
and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.
The issuance of preferred stock could decrease
the amount of earnings and assets available for distribution to the holders of Common Stock or adversely affect the rights and powers,
including voting rights, of the holders of Common Stock. The issuance of preferred stock, while providing flexibility in connection with
possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a
change in control of the Company, which could depress the market price of our Common Stock.
Voting Rights
Except as otherwise expressly provided by the
amended and restated certificate of incorporation or as provided by law, the holders of shares of Common Stock and Preferred Stock shall
at all times vote together as a single class on all matters (including the election of directors) submitted to a vote of the stockholders;
provided, however, that, any proposal which adversely affects the rights, preferences and privileges of the Series A, B, C or D
Preferred Stock must be approved by a majority in interest of the affected Series of Preferred Stock, as the case may be. Each holder
of Common Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock will have the right to
one vote per share (on a fully converted basis) held of record by such holder and each holder of Series A Preferred Stock will have
the right to 1000 votes per share (on a fully converted basis) held of record by such holder; provided, however, that after November 5,
2024, each holder of Series A Preferred Stock will have the right to one vote per share (on a fully converted basis) held of record
by such holder.
Series A Preferred Stock
200,000 shares of Preferred Stock
are designated as Series A Preferred Stock.
| |
· |
Conversion. The Series A Preferred Stock is convertible at the option of each holder
at any time on a 100-for-1 basis (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like
with respect to the Common Stock). The Series A Preferred Stock will automatically convert into shares of Common Stock on a
100-for-1 basis (as so adjusted) upon the earlier of (i) a Qualified Public Offering (as such term is defined in the amended
and restated certificate of incorporation) or (ii) the date specified by written consent or agreement of the holders of the
then outstanding shares of Series A Preferred Stock. |
Series B Preferred Stock
12,000,000 shares of Preferred Stock are designated as
Series B Preferred Stock.
| |
· |
Conversion. The Series B Preferred Stock is convertible at the option of each holder
at any time into the number of shares of Common Stock determined by dividing the Series B Original Issue Price (plus all unpaid
accrued and accumulated dividends thereon, as applicable, whether or not declared), by the Series B Conversion Price, as applicable
(in each case, the “Conversion Rate”), in effect on the date the certificate is surrendered for conversion. “Series B
Original Issue Price” means $0.6877 per share for each share of the Series B Preferred Stock (as adjusted for any stock
splits, stock dividends, combinations, recapitalizations or the like with respect to the Series B Preferred Stock). The initial
“Series B Conversion Price” is the Series B Original Issue Price, subject to adjustment as set forth in the
amended and restated certificate of incorporation. Based on this formula, the Series B Preferred Stock is currently convertible
into Common Stock on a 1-for-1 basis. The Series B Preferred Stock will automatically convert into shares of Common Stock upon
the earlier of (i) a Qualified Public Offering (as such term is defined in the amended and restated certificate of incorporation)
or (ii) the date specified by written consent or agreement of the holders of the then outstanding shares of Series B Preferred
Stock. The Series B Preferred Stock will not be convertible by a holder to the extent that the holder or any of its affiliates
would beneficially own in excess of 9.99% of the Common Stock, subject to certain protections as provided in the amended and restated
certificate of incorporation. |
Series C Preferred Stock
40,000,000 Shares of Preferred Stock are designated as
Series C Preferred Stock.
| |
· |
Conversion. The Series C Preferred Stock is convertible at the option of each holder
at any time into the number of shares of Common Stock determined by dividing the Series C Original Issue Price (plus
all unpaid accrued and accumulated dividends thereon, as applicable, whether or not declared), by the Series C Conversion Price,
as applicable (in each case, the “Conversion Rate”), in effect on the date the certificate is surrendered for conversion.
The initial “Series C Conversion Price” is the Series C Original Issue Price, subject to adjustment as set
forth in the amended and restated certificate of incorporation. Based on this formula, the Series C Preferred Stock is currently
convertible into Common Stock on a 1-for-1 basis. All of the Series C Preferred Stock shall automatically convert into Common
Stock at any such time as (i) the shares underlying the Series C Preferred Stock are subject to an effective registration
statement, (ii) the trading price for the Common Stock is more than two times the Series C Conversion Price for twenty
(20) trading days in any period of thirty (30) consecutive trading days on Nasdaq CM and (iii) the average daily trading dollar
volume of the Common Stock during such twenty trading days is equal to or greater than $4.0 million. The Series C Preferred
Stock will not be convertible by a holder to the extent that the holder or any of its affiliates would beneficially own in excess
of 9.99% of the Common Stock, subject to certain protections as provided in the amended and restated certificate of incorporation. |
| |
· |
Dividends. The Series C Preferred Stock bears a cumulative 15.0% per annum fixed dividend
payable no later than the 5th day after the end of each month on the Series C Original Issue Price plus unpaid accrued and accumulated
dividends. “Series C Original Issue Price” means $0.6877 per share for each share of the Series C Preferred
Stock (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like with respect to the Series C
Preferred Stock). Dividends on the Series C Preferred Stock are prior to any dividends on any other series of Preferred Stock
or the Common Stock. The Company may elect to pay dividends for any month with a paid-in-kind election (“PIK”) if (i) the
shares issuable further to the PIK are subject to an effective registration statement, (ii) the Company is then in compliance
with all listing requirements of Nasdaq and (iii) the average daily trading dollar volume of the Company’s common stock
for ten trading days in any period of twenty consecutive trading days on the NASDAQ is equal to or greater than $2 million. |
| |
· |
Redemption Rights. There is no mandatory redemption date, but, subject to the conditions
set forth below, all, but not less than all, of the shares are redeemable by the Company at any time, provided that if the Company
issues notice to redeem, investor shall have fifteen (15) days to convert such shares to common stock prior to the date of redemption.
The redemption price is equal to the Series C Original Issue Price, plus accrued and accumulated dividends, (whether or not
declared (the “Series C Redemption Price”). The conditions to the redemption are as follows: (i) the shares
have been issued and outstanding for at least one (1) year, (ii) the issuance of the shares of Common Stock underlying
the shares has been registered pursuant to the Securities Act and the registration statement is effective, and (iii) the trading
price for the Common Stock is less than the Series C Conversion Price (as such term is defined in the amended and restated certificate
of incorporation) for twenty (20) trading days in any period of thirty (30) consecutive trading days on the Nasdaq CM. In addition
to the above, the shares are also redeemable in accordance with the following schedule provided the issuance of shares of Common
Stock underlying the shares has been registered and the registration statement remains effective: |
| |
· |
Year 2: Redemption at 120% of the Series C Redemption Price |
| |
· |
Year 3: Redemption at 115% of the Series C Redemption Price |
| |
· |
Year 4: Redemption at 110% of the Series C Redemption Price |
| |
· |
Year 5: Redemption at 105% of the Series C Redemption Price |
| |
· |
Year 6 and thereafter: Redemption at 100% of the Series C Redemption Price |
Series D Preferred Stock
437,500,001 Shares of Preferred Stock are designated as
Series D Preferred Stock.
Voting Rights. Except as provided by law,
the Series D Preferred Stock will have no voting rights except that approval from a majority in interest of the Series D Preferred
Stock, voting as a separate class, is required in the case of (i) a voluntary dissolution, liquidation or winding up of the Company
or voluntary petition for bankruptcy or assignment for the benefit of creditors, (ii) a merger or consolidation of the Company with
or into another entity, (iii) a Liquidation Event (as defined in the Company’s Second Amended and Restated Certificate of
Incorporation), (iv) any amendment to the Second Amended and Restated Certificate of Incorporation or the Company’s bylaws
which adversely affects the rights, preferences and privileges of the Series D Preferred, or (v) any authorization or issuance
of any equity security (including any other security convertible into or exercisable for any such equity security) having a preference
over or parity with the Series D Preferred Stock.
Conversion. The Series D Preferred
Stock is automatically converted into shares of Common Stock at the applicable Conversion Rate at the time in effect immediately upon
(A) the issuance of shares of Common Stock underlying the Series D Preferred Stock being registered pursuant to the Securities
Act and such registration remaining effective, (B) the trading price for the Company’s Common Stock being more than two times
the Series D Conversion Price for 20 trading days in any period of 30 consecutive trading days on the Nasdaq Capital Market, and
(C) the average daily trading dollar volume of Common Stock during such 20 trading days is equal to or greater than $27.5 million.
The Series D Preferred Stock is convertible at the option of each holder at any time into the number of shares of Common Stock determined
by dividing the Series D Original Issue Price (plus all unpaid accrued and accumulated dividends thereon, as applicable, whether
or not declared), by the Series D Conversion Price (the “Conversion Rate”), in effect on the date the certificate is
surrendered for conversion. The initial “Series D Conversion Price” is the Series D Original Issue Price, subject
to adjustment as set forth in the amended and restated certificate of incorporation. The Series D Preferred Stock will not be convertible
by a holder to the extent that the holder or any of its affiliates would beneficially own in excess of 9.99% of the Common Stock, subject
to certain protections as provided in the amended and restated certificate of incorporation.
Dividends. The Series D Preferred
Stock bears a cumulative 15.0% per annum fixed dividend payable no later than the 5th day after the end of each month on the Series D
Original Issue Price plus unpaid accrued and accumulated dividends. “Series D Original Issue Price” means for each share
of the Series D Preferred Stock the lower of (i) $1.27 or (ii) the closing price of the Common Stock on the trading day
immediately preceding the Purchase Date (as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like
with respect to the Series D Preferred Stock). Dividends on the Series D Preferred Stock will be prior to any dividends on
any other series of Preferred Stock or the Common Stock. The Company may elect to pay dividends for any month with a paid-in-kind election
(“PIK”) if (i) the shares issuable further to the PIK are subject to an effective registration statement, (ii) the
Company is then in compliance with all listing requirements of Nasdaq and (iii) the average daily trading dollar volume of the Company’s
common stock for ten trading days in any period of twenty consecutive trading days on the NASDAQ is equal to or greater than $27.5 million.
Redemption Rights. There is no mandatory
redemption date, but, subject to the conditions set forth below, all, but not less than all, of the shares will be redeemable by the
Company at any time, provided that if the Company issues notice to redeem, investors shall have 15 days to convert such shares to Common
Stock prior to the date of redemption. The redemption price will be equal to the Series D Original Issue Price, plus accrued and
accumulated dividends, (whether or not declared (the “Series D Redemption Price”). The conditions to the redemption
will be follows: (i) the shares have been issued and outstanding for at least one year, (ii) the issuance of the shares of
Common Stock underlying the shares has been registered pursuant to the Securities Act and the registration statement is effective, and
(iii) the trading price for the Common Stock is less than the Series D Conversion Price (as such term is defined in the amended
and restated certificate of incorporation) for 20 trading days in any period of 30 consecutive trading days on the Nasdaq CM. In addition
to the above, the shares will also be redeemable in accordance with the following schedule provided the issuance of shares of Common
Stock underlying the shares has been registered and the registration statement remains effective:
| |
· |
Year 2: Redemption at 120% of the Series D Redemption Price |
| |
· |
Year 3: Redemption at 115% of the Series D Redemption Price |
| |
· |
Year 4: Redemption at 110% of the Series D Redemption Price |
| |
· |
Year 5: Redemption at 105% of the Series D Redemption Price |
| |
· |
Year 6 and thereafter: Redemption at 100% of the Series D Redemption Price |
Anti-Takeover Effects of Certain Provisions of Delaware Law and
Our Certificate of Incorporation and Bylaws
Our Certificate of Incorporation, as amended,
and Bylaws, as amended contain provisions that could have the effect of discouraging potential acquisition proposals or tender offers
or delaying or preventing a change of control. These provisions, summarized below, are expected to discourage certain types of coercive
takeover practices and inadequate takeover bids and are designed to encourage persons seeking to acquire control of us to negotiate with
our board of directors. We believe that the benefits of increased protection against an unfriendly or unsolicited proposal to acquire
or restructure us outweigh the disadvantages of discouraging such proposals. Among other things, negotiation of such proposals could
result in an improvement of their terms. These provisions are as follows:
| |
· |
Stockholder Meetings. Under our bylaws, only the Board of Directors, the chairman of the
Board, the chief executive officer, or the president (in the absence of a chief executive officer) may call special meetings of stockholders. |
| |
· |
No Cumulative Voting. Our amended and restated certificate of incorporation and bylaws do
not provide for cumulative voting in the election of directors. |
| |
· |
Amendment of Provisions in the Amended and Restated Certificate of Incorporation. The amended
and restated certificate of incorporation will generally require the affirmative vote of the holders of at least a majority of the
outstanding voting stock in order to amend any provisions of the amended and restated certificate of incorporation concerning, among
other things: |
| |
· |
the required vote to amend certain provisions of the amended and restated certificate of incorporation;
and |
| |
|
|
| |
· |
the reservation of the Board of Director’s right to amend the amended and restated bylaws. |
| |
|
|
| |
· |
Amendment of the bylaws. An amendment of the bylaws by stockholders requires the affirmative vote of the holders of at
least a majority of the outstanding voting stock. |
We are subject to the provisions of Section 203
of the Delaware General Corporation Law, an anti- takeover law. Subject to certain exceptions, the statute prohibits a publicly held
Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period
of three years after the date of the transaction in which the person became an interested stockholder unless:
| |
· |
prior to such date, the board of directors of the corporation approved either the business combination
or the transaction which resulted in the stockholder becoming an interested stockholder; |
| |
· |
upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder,
the interested stockholder owned at least eighty-five percent 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned (1) by
persons who are directors and also officers and (2) by employee stock plans in which employee participants do not have the right
to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
| |
· |
on or after such date, the business combination is approved by the board of directors and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-thirds
percent 662∕3% of the outstanding voting stock that is not owned by the interested stockholder. |
Generally, for purposes of Section 203,
a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to
the interested stockholder. An “interested stockholder” is a person who, together with affiliates and associates, owns or,
within three (3) years prior to the determination of interested stockholder status, owned fifteen percent (15%) or more of a corporation’s
outstanding voting securities.
Potential Effects of Authorized but Unissued Stock
We have shares of common stock and preferred
stock available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes,
including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital
stock.
The existence of unissued and unreserved common
stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or to issue preferred
stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender
offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, the board of directors has the discretion
to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights,
redemption privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the
DGCL and subject to any limitations set forth in our Certificate of Incorporation. The purpose of authorizing the board of directors
to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated
with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with
possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party to
acquire, or could discourage a third-party from acquiring, a majority of our outstanding voting stock.
Warrants
The following description, together with the
additional information we may include in any applicable prospectus supplement and free writing prospectus, summarizes the material terms
and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase Common Stock and may
be issued in one or more series. Warrants may be offered independently or in combination with Common Stock or Preferred Stock offered
by any prospectus supplement. While the terms we have summarized below will apply generally to any warrants that we may offer under this
prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The
following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable
prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms.
We have filed a form of the warrant agreement
and warrant certificate containing the terms of the warrants that may be offered as exhibits to the registration statement of which this
prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate
by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable,
that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of
such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety
by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any
supplemental agreements applicable to a particular series of warrants that we or selling securityholders may offer under this prospectus.
We urge you to read the applicable prospectus supplement related to the particular series of warrants that we or selling securityholders
may offer under this prospectus, as well as any related free writing prospectus, and the complete form of warrant and/or the warrant
agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants.
General
We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including:
| · |
the offering price and aggregate number of warrants offered; |
| · |
the currency for which the warrants may be purchased; |
| · |
if applicable, the designation and terms of the securities with which the warrants are issued and
the number of warrants issued with each such security or each principal amount of such security; |
| · |
in the case of warrants to purchase Common Stock, the number of shares of Common Stock purchasable
upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; |
| · |
the effect of any merger, consolidation, sale or other disposition of our business on the warrant
agreement and the warrants; |
| · |
the terms of any rights to redeem or call the warrants; |
| · |
any provisions for changes to or adjustments in the exercise price or number of securities issuable
upon exercise of the warrants; |
| · |
the dates on which the right to exercise the warrants will commence and expire; |
| · |
the manner in which the warrant agreement and warrants may be modified; |
| · |
a discussion of material or special U.S. federal income tax considerations, if any, of holding
or exercising the warrants; |
| · |
the terms of the securities issuable upon exercise of the warrants; and |
| · |
any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders of
warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive
dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
Exercise of Warrants
Each warrant will entitle the holder to purchase
the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus
supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise
specify in the applicable prospectus supplement, warrants may be exercised at any time up to the close of business on the expiration
date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date,
unexercised warrants will become void.
Upon receipt of payment and the warrant or warrant
certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other
office, including ours, as indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities
purchasable upon such exercise. If less than all of the warrants (or the warrants represented by such warrant certificate) are exercised,
a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants.
Governing Law
Unless we provide otherwise in the applicable
prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the internal laws
of the State of New York.
Enforceability of Rights by Holders of Warrants
Each warrant agent, if any, will act solely as our agent under the
applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A
single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility
in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any
proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant
agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable
upon exercise of, its warrants.
Transfer Agent and Registrar
The transfer agent and registrar
for our Common Stock is Continental Stock Transfer & Trust Company.
LEGAL MATTERS
Unless otherwise indicated in the applicable
prospectus supplement, the validity of the securities offered hereby will be passed upon for us by McDermott, Will & Emery LLP.
If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel
for the underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering.
EXPERTS
The consolidated financial statements at September 30,
2022 and 2021 and for the years then ended incorporated by reference in this prospectus have been so incorporated in reliance on the
report of Daszkal Bolton LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority
of said firm as experts in auditing and accounting.
ADDITIONAL INFORMATION
This prospectus is part of a registration statement
on Form S-3 that we have filed with the SEC relating to the securities being offered hereby. This prospectus does not contain all
of the information in the registration statement and its exhibits. The registration statement, its exhibits and the documents incorporated
by reference in this prospectus and their exhibits, all contain information that is material to the offering of the securities hereby.
Whenever a reference is made in this prospectus to any of our contracts or other documents, the reference may not be complete. You should
refer to the exhibits that are a part of the registration statement in order to review a copy of the contract or documents. The registration
statement and the exhibits are available at the SEC’s Public Reference Room or through its website.
We file annual, quarterly and current reports,
proxy statements and other information with the SEC. You can read and copy any materials we file with the SEC at its Public Reference
Room at 100 F Street, N.E., Washington, D.C. 20549 and at its regional offices, a list of which is available on the Internet at http://www.sec.gov/contact/addresses.htm.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet
site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, such as
us, that file electronically with the SEC. Additionally, you may access our filings with the SEC through our website at https://investors.mullenusa.com/.
The information on our website is not part of this prospectus.
We will provide you without charge, upon your
oral or written request, with a copy of any or all reports, proxy statements and other documents we file with the SEC, as well as any
or all of the documents incorporated by reference in this prospectus or the registration statement (other than exhibits to such documents
unless such exhibits are specifically incorporated by reference into such documents). Requests for such copies should be directed to:
Mullen Automotive Inc.
Attn: David Michery, President, CEO and Chairman
1405 Pioneer St
Brea, CA 92821
(714) 613-1900
You should rely only on the information in this
prospectus and the additional information described above and under the heading “Incorporation of Certain Information by Reference”
below. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely upon it. We are not making an offer to sell these securities in any jurisdiction where the offer or
sale is not permitted. You should assume that the information in this prospectus was accurate on the date of the front cover of this
prospectus only. Our business, financial condition, results of operations and prospects may have changed since that date.
INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE
The SEC allows us to “incorporate by reference”
information that we file with it into this prospectus, which means that we can disclose important information to you by referring you
to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by
reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and
supersede information contained in this prospectus and any accompanying prospectus supplement.
We incorporate by reference the documents listed
below that we have previously filed with the SEC:
| |
· |
The
Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2022, as filed with the Commission on
January 13, 2023, as amended by Amendment
No. 1 to our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed with the Commission on
January 30, 2023. |
| |
|
|
| |
· |
The
Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2022, filed with the Commission on February 14,
2023. |
| |
|
|
| |
· |
The Company’s Current Reports on Form 8-K filed with the Commission on October 14,
2022, October 17,
2022, November 14,
2022 (Two
Filings), November 21,
2022, December 2,
2022, December 15,
2022, December 23,
2022, January 13,
2023, January 23,
2023 and January 31,
2023. |
| |
|
|
| |
· |
The description of the Company’s securities contained in the Prospectus,
dated April 15, 2022, filed with the Commission on April 18, 2022 pursuant to Rule 424(b)(4) under the Securities
Act (File No. 333-263880), relating to the Company’s registration statement on Form S-3
(File No. 333-263880) filed with the Commission on March 28, 2022, together with any amendment thereto filed with the
Commission for the purpose of updating such description. |
All reports and other documents that we file
with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement and
prior to effectiveness of the registration statement and after the date of this prospectus but before the termination of the offering
of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing
of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information
that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide
without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request,
a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically
incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading
“Additional Information,” above.
MULLEN AUTOMOTIVE INC.
242,124,674 Shares
of Common Stock
PROSPECTUS SUPPLEMENT
June 5, 2023
Net Element (NASDAQ:NETE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Net Element (NASDAQ:NETE)
Historical Stock Chart
From Apr 2023 to Apr 2024
